目的：观察左旋多巴联合应用普拉克索对原发性不宁腿综合征（RLS）患者的疗效。方法：中~重度原 发性RLS患者30例，随机分为对照组和联合组各15例，2组均予普拉克索0.25~0.75 mg/d，联合组还予美多 巴62.5～125 mg/d，治疗6周。利用RLS严重程度量表（IRLS）、临床总体印象改善量表（CGI-I）、患者总体印 象量表（PGI）和Epworth嗜睡量表（ESS）评估患者治疗前后的RLS症状严重程度和嗜睡程度，同时记录不良 反应。结果：2 组治疗后 IRLS 评分均低于治疗前(P＜0.05)；联合组治疗后的 IRLS 评分低于对照组(P＜ 0.05)。治疗后，联合组的CGI-I及PGI评估显效率高于普拉克索组 (P＜0.05)。2组治疗后ESS评分均低于 治疗前 (P＜0.05)，2组治疗后的ESS评分差异无统计学意义(P＞0.05)。结论：左旋多巴联合应用普拉克索 对原发性RLS的疗效优于单用普拉克索。

To demonstrate the efficacy of pramipexole combined with L-dopa on patients with idiopathic restless legs syndrome (RLS). Methods: Thirty patients with moderate to severe RLS were randomly divided into the control group and combined group with 15 patients in each. During the 6 weeks of treatment, both groups were given Pramipexole (0.25~0.75 mg/d), and the combined group was additionally given Madopar (62.5~125 mg/d). The international RLS scale (IRLS)，patient global impression (PGI) scale, clinical global impressions-improvement (CGI-I) scale, and Epworth sleepiness scale (ESS) were used to evaluate RLS symptom severity and sleepiness before and after treatment; incidence of adverse events was also recorded throughout the trial. Results: IRLS scores decreased after therapy both in both groups (P＜0.05), and the post-treatment IRLS score in the combined group was lower than that in the control group (P＜0.05). After therapy, CGI-I and PGI scores of the combined group were significantly greater than that in the control group (P＜0.05). ESS scores decreased after therapy in both groups (P＜0.05), and there was no statistical difference between the post-treatment ESS scores of the two groups (P＞0.05). Conclusion: The efficacy of pramipexole combined with L-dopa in the treatment of idiopathic RLS is greater than that of pramipexole alone.